Stay updated on Anti-PD1 Brain Collaboration Clinical Trial

Sign up to get notified when there's something new on the Anti-PD1 Brain Collaboration Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Anti-PD1 Brain Collaboration Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Revision: v3.4.1 was added and Revision: v3.4.0 was removed, indicating a version update with no changes to the study details on the page.
    Difference
    0.0%
    Check dated 2026-02-06T09:18:24.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Glossary toggle controls were added (Show glossary / Hide glossary) and update metadata labels were refreshed (Last Update Submitted that Met QC Criteria, Last Update Posted) with a new Revision tag. The older QC label (Last Update Submitted that met QC Criteria), the estimated Last Update Posted, the No FEAR Act data label, and Revision: v3.3.4 were removed.
    Difference
    0.4%
    Check dated 2026-01-22T17:48:39.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no changes to study details or page content are evident, and to avoid alerts for small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T10:51:21.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    The page now includes an expanded Locations section listing New South Wales, Queensland, South Australia, and Victoria, along with updated metadata (Last Update Posted (Estimated) and Revision: v3.3.3). Older state-specific headings and the previous revision number were removed.
    Difference
    0.6%
    Check dated 2025-12-17T19:08:27.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Added a new site in Wollstonecraft, New South Wales, Australia (2065). The dosing schedule was updated to allow nivolumab 480 mg every 4 weeks after 52 weeks, and the study completion window was extended to up to 10 years, with expanded biomarker plans (PD-L1 status, immune markers) and scheduled blood/tissue sampling.
    Difference
    0.6%
    Check dated 2025-12-10T16:45:26.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Publications section now notes that items are automatically filled from PubMed, and the revision tag was updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-26T13:49:39.000Z thumbnail image

Stay in the know with updates to Anti-PD1 Brain Collaboration Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Anti-PD1 Brain Collaboration Clinical Trial page.